Drug profile · INN
lenvatinib mesilate
LENVIMA INITIAL APPROVAL
lenvatinib mesilate (LENVIMA INITIAL APPROVAL) is a vascular endothelial growth factor receptor inhibitor.
PMDA: approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — lenvatinib mesilate
- Class
- —
- Route
- —
- Patents
- 0
- Programs
- 0
- Data quality
- 0.78
Quick answer
lenvatinib mesilate (LENVIMA INITIAL APPROVAL) is a vascular endothelial growth factor receptor inhibitor.
Key facts
INN lenvatinib mesilate
Brand LENVIMA INITIAL APPROVAL
Mechanism Vascular endothelial growth factor receptor inhibitor
Target Vascular endothelial growth factor receptor
Mechanism of action
Vascular endothelial growth factor receptor inhibitor
Primary target: Vascular endothelial growth factor receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| PMDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is lenvatinib mesilate?
lenvatinib mesilate (LENVIMA INITIAL APPROVAL) is a vascular endothelial growth factor receptor inhibitor.
What is the brand name for lenvatinib mesilate?
LENVIMA INITIAL APPROVAL is a marketed brand name for lenvatinib mesilate. Check FDA Drugs@FDA for the current US label holder and prescribing information.